United Advisor Group’s Vertex Pharmaceuticals VRTX Stock Holding History

United Advisor Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$268K	Sell	539 -6	-1%	-$2.66K	0.03%	450
2026 Q1	$243K	Buy	545 +77	+16%	+$35.9K	0.03%	445
2025 Q4	$212K	Sell	468 -270	-37%	-$116K	0.03%	457
2025 Q3	$289K	Buy	738 +144	+24%	+$60.2K	0.04%	363
2025 Q2	$264K	Buy	+594	New	+$274K	0.05%	333
2024 Q4	–	Sell	-434	Closed	-$202K	–	401
2024 Q3	$202K	Buy	+434	New	+$208K	0.05%	336

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

United Advisor Group's VRTX Position: Q2 2026 in Review

United Advisor Group reduced its Vertex Pharmaceuticals (VRTX) stake by 1.1% in Q2 2026, selling an estimated $2.66K and leaving 539 shares worth $268K. The position accounts for 0.03% of the portfolio, ranked #450.

United Advisor Group first reported a position in VRTX in Q3 2024 and has held it in 6 quarters since. The position peaked at $289K in Q3 2025. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

United Advisor Group held 539 shares of Vertex Pharmaceuticals worth $268K as of Q2 2026.
United Advisor Group sold 6 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.66K.
Vertex Pharmaceuticals made up 0.03% of United Advisor Group's portfolio in Q2 2026, its #450 holding.
United Advisor Group first reported a position in Vertex Pharmaceuticals in Q3 2024 and has held it in 6 quarters since.
United Advisor Group's Vertex Pharmaceuticals position peaked at $289K in Q3 2025.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on United Advisor Group's 13F filing for Q2 2026, filed 29 Jul 2026.